Noxopharm announcement that scientific data from DARRT-1 and LuPIN prostate cancer treatment studies included in two major oncology conferences this year, as covered by Biotech Dispatch
Australian drug development company Noxopharm™ to present interim results on new prostate cancer treatment at specialist oncology conferences in Australia and overseas
US digital medical magazine Healthcare Tech Outlook profiling the enhancing effect of Veyonda on radiotherapy seen in pre-clinical trials and in clinical trials with men with prostate cancer.
Video: CEO Dr Greg van Wyk discusses anti-prostate cancer drug Veyonda, its efficacy in prostate cancer treatment, the drug’s upside and the company’s strategy for growth.
Independent news service, Biotech Dispatch interviews Noxopharm Founder and Exec Chairman Dr Graham Kelly on Veyonda's effect on cancer cells and the immune system.
AddressLevel 4, 828 Pacific Highway Gordon. 2072 NSW AUSTRALIA
PO Box 292, Gordon
2072 NSW AUSTRALIA
50 608 966 123
Join our mailing list to receive the latest information from Noxopharm Limited